Abstract
In recent years, the transient receptor potential melastatin member 8 (TRPM8) channel has emerged as a promising prognostic marker and putative therapeutic target in prostate cancer. We have found that forced overexpression of TRPM8 in PC-3 cells can inhibit the cell proliferation and motility probably through the TRPM8 activation. In this study, we aimed to investigate whether activating the TRPM8 channel by its selective agonist menthol can inhibit the proliferation and motility of androgen-independent prostate cancer (AIPC) with remarkable expression of TRPM8. Menthol is a naturally occurring compound, which has been widely used in cosmetics and pharmaceutical products, and also as flavoring in food. DU145 cells are androgen-independent but have a remarkable expression of TRPM8. The demonstration of the existence of TRPM8 and the absence of TRPA1 in DU145 cells provided the foundation for the following experiments, because both TRPM8 and TRPA1 are molecular targets of menthol. The outcome of MTT assay indicated that menthol inhibited the cell growth (p < 0.01). Cell cycle distribution and scratch assay analysis revealed that menthol induced cell cycle arrest at the G0/G1 phase (p < 0.01). Furthermore, menthol inhibited the migration of DU145 cells by downregulating the focal-adhesion kinase. So it suggests that the activation of the existing TRPM8 channels may serve as a potential and pragmatic treatment for those AIPC with remarkable expression of TRPM8, and menthol is a useful compound for future development as an anticancer agent.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66
Chen Y, Clegg NJ, Scher HI (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10(10):981–991
Rosenthal SA, Sandler HM (2010) Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol 7(1):31–38
Taplin ME (2007) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 4(4):236–244
Damber JE, Aus G (2008) Prostate cancer. Lancet 371(9625):1710–1721
Legrand G, Humez S, Slomianny C et al (2001) Ca2+ pools and cell growth. Evidence for sarcoendoplasmic Ca2+-ATPases 2B involvement in human prostate cancer cell growth control. J Biol Chem 276(50):47608–47614
Thebault S, Flourakis M, Vanoverberghe K et al (2006) Differential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res 66(4):2038–2047
Vanoverberghe K, Vanden Abeele F, Mariot P et al (2004) Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ 11(3):321–330
Skryma R, Mariot P, Bourhis XL et al (2000) Store depletion and store-operated Ca2+ current in human prostate cancer LNCaP cells: involvement in apoptosis. J Physiol 527(Pt 1):71–83
Vanden Abeele F, Skryma R, Shuba Y et al (2002) Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells. Cancer Cell 1(2):169–179
Vanden Abeele F, Roudbaraki M, Shuba Y, Skryma R, Prevarskaya N (2003) Store-operated Ca2+ current in prostate cancer epithelial cells. Role of endogenous Ca2+ transporter type 1. J Biol Chem 278(17):15381–15389
Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ (2007) Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer 7(7):519–530
Tsavaler L, Shapero MH, Morkowski S, Laus R (2001) Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 61(9):3760–3769
Henshall SM, Afar DE, Hiller J et al (2003) Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63(14):4196–4203
Yang ZH, Wang XH, Wang HP, Hu LQ (2009) Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells. Asian J Androl 11(2):157–165
Patel T, Ishiuji Y, Yosipovitch G (2007) Menthol: a refreshing look at this ancient compound. J Am Acad Dermatol 57(5):873–878
McKemy DD, Neuhausser WM, Julius D (2002) Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416(6876):52–58
Peier AM, Moqrich A, Hergarden AC et al (2002) A TRP channel that senses cold stimuli and menthol. Cell 108(5):705–715
Zhang L (2004) Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells. Cancer Res 64(22):8365–8373
Valero M, Morenilla-Palao C, Belmonte C, Viana F (2010) Pharmacological and functional properties of TRPM8 channels in prostate tumor cells. Pflugers Arch-Eur J Physiol 461(1):99–114
Kim S, Nam J, Park E, Kim B, So I, Jeon J (2009) Menthol regulates TRPM8-independent processes in PC-3 prostate cancer cells. BBA-Mol Basis Dis 1792(1):33–38
Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS (2005) Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 434(7034):786–792
Story GM, Peier AM, Reeve AJ et al (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112(6):819–829
Bidaux G, Roudbaraki M, Merle C et al (2005) Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement. Endocr Relat Cancer 12(2):367–382
RIFM (Research Institute for Fragrance Materials, Inc.) (1975) Mutagenic evaluation of compound FDA 71–57, menthol. NTIS PB-245-444 (FDA 71–268). Unpublishee report from Food and Drug Administration, 14 January. Report Number 5713, RIFM, Woodcliff Lake, NJ, USA
Bernson VSM, Pettersson B (1983) The toxicity of menthol in short-term bioassays. Chem-Biol Interactions 46:233–246
Yamamura H, Ugawa S, Ueda T, Morita A, Shimada S (2008) TRPM8 activation suppresses cellular viability in human melanoma. Am J Physiol Cell Physiol 295:C296–C301
Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8(7):547–566
Pines J (1995) Cyclins and cyclin-dependent kinases: a biochemical view. Biochem J 308(Pt 3):697–711
Brooke GN, Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10(1):18–25
Schlaepfer DD, Mitra SK, Ilic D (2004) Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692(2–3):77–102
Acknowledgments
This study was supported by a grant of Natural Science Foundation of China (N0.81172734).
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s12253-015-0039-0.
Rights and permissions
About this article
Cite this article
Wang, Y., Wang, X., Yang, Z. et al. Menthol Inhibits the Proliferation and Motility of Prostate Cancer DU145 Cells. Pathol. Oncol. Res. 18, 903–910 (2012). https://doi.org/10.1007/s12253-012-9520-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-012-9520-1